Xenetic Biosciences, Inc. lost $1.58 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to a loss of $1.55 per diluted share. The table below carries 14 fiscal years, from 2012 to 2025, and the quarters Xenetic Biosciences, Inc. has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Xenetic Biosciences, Inc. lost $1.58 per diluted share in fiscal year 2025.
Xenetic Biosciences, Inc. (XBIO) reported a loss of $2.57 per diluted share in fiscal year 2024 and a loss of $1.58 per diluted share in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Xenetic Biosciences, Inc. (XBIO) reported a loss of $1.55 per diluted share over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 14 fiscal years this page covers, Xenetic Biosciences, Inc. (XBIO) diluted earnings per share went from -$6.00 in fiscal year 2012 to -$1.58 in fiscal year 2025.
Xenetic Biosciences, Inc. (XBIO) reported -$0.72 in diluted earnings per share in Q3 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Xenetic Biosciences, Inc. (XBIO) reported on that line in every period on record.